Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
Gillian M Duchesne, Henry H Woo, Julie K Bassett, Steven J Bowe, Catherine D'Este, Mark Frydenberg, Madeleine King, Leo Ledwich, Andrew Loblaw, Shawn Malone, Jeremy Millar, Roger Milne, Rosemary G Smith, Nigel Spry, Martin Stockler, Rodney A Syme, Keen Hun Tai, Sandra Turner
The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2016
Awarded by Australian National Health and Medical Research Council and Cancer Councils
Cancer Council Victoria sponsored the trial. The trial was supported by peer-reviewed grants from the Australian National Health and Medical Research Council and Cancer Councils (number 350201), The Royal Australian and New Zealand College of Radiologists, and by an educational grant from Mayne Pharma Australia (now part of the Pfizer group). We thank the trial coordinating and contributing centres' staff, the statisticians who have previously guided the trial, and the patients who entered the study.